Stability, speed and strategy: Inside Australia’s early‑stage edge

0:00-21:19

In this episode of Denatured, you’ll hear from Jerome Barley, commercial director at Avion Medical and Ryan Klein, vice president, business development, US and APAC at Resolian. We discuss why Australia has become a magnet for early clinical development, and whether its speed, regulatory clarity and tax incentives are pushing it toward a more integrated biotech role. Host Jennifer C. Smith-Parker, Director of Insights, BioSpace Guests Jerome Barley, Commercial Director, Avion Medical Ryan Klein, Vice President, Business Development, US and APAC, Resolian Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Publisher

BioSpace

Published

October 29, 2026

Duration

21 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

B

BioSpace

@biospace

#stability #australiasearly #stageedge #lifesciences

The Nile